Explore the words cloud of the LCxLCProt project. It provides you a very rough idea of what is the project "LCxLCProt" about.
The following table provides information about the project.
|Coordinator Country||Belgium [BE]|
|Total cost||89˙160 €|
|EC max contribution||89˙160 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2020-01-01 to 2020-12-31|
Take a look of project's partnership.
Protein biopharmaceuticals, which globally represent about 20 % of the total pharmaceutical market, are becoming increasingly popular in the treatment of various diseases. Experts forecast that over 50 % of new drug approvals in the next decade will be for biologics, especially monoclonal antibodies. Very accurate structural characterization and purity analysis is required during both the development of the new drugs, and later during manufacturing for quality control purposes. Biopharmaceutical protein molecules are very large and heterogeneous, which makes their characterization very difficult. The goal of this project is to develop novel methods for the characterization of protein biopharmaceuticals at the protein level based on comprehensive two-dimensional liquid chromatography (LC×LC). Two approaches will be explored: the use of reversed phase separation mechanism in both dimensions with parallel gradients, and application of thermally responsive stationary phases for thermal modulation of LC×LC fractions. Parallel gradients provide the greatest orthogonality when the separation mechanisms in both dimensions are correlated, and allow the use of short modulation periods, which together lead to a dramatic increase in peak capacity (as demonstrated in preliminary experiments). Thermally responsive stationary phases allow trapping of the analyte bands at elevated temperatures, and their release at low temperature. This is compatible with intact protein analysis, especially when ion exchange is used in the first dimension of the LC×LC system. It is expected that the research will result in new, cutting edge methods for the analysis and characterization of protein biopharmaceuticals that will be applicable under the good manufacturing practice (GMP) conditions, improving the quality assurance/quality control and increasing the confidence in the pharmaceuticals.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LCXLCPROT" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "LCXLCPROT" are provided by the European Opendata Portal: CORDIS opendata.
State disintegration in the context of macroeconomic crisis - the case of YugoslaviaRead More
Light-enabled transport phenomena in van der Waals heterostructuresRead More
Ligand Directed NIR-based Theranostic Prodrugs for Prostate CancerRead More